Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

InnoCare Announces First Patient Dosed in the Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China

Summary by The Toronto Star
BEIJING, Feb. 12, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the

7 Articles

WellandTribune.caWellandTribune.ca
+6 Reposted by 6 other sources
Lean Left

InnoCare Announces First Patient Dosed in the Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China

BEIJING, Feb. 12, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the Phase II/III clinical…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Left
100% Left

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

The Hamilton Spectator broke the news in Hamilton, Canada on Thursday, February 12, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Beijing icon

Beijing

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal